We’re dsm-firmenich – innovators in nutrition, health, and beauty

Share price:


Purpose-driven performance

dsm-firmenich brings together two iconic companies. We have deep roots and a bright future, with shared strengths and unrivaled expertise that drive positive impact in everything we do. Our purpose is to bring progress to life – creating a world of potential for customers, communities, consumers, and investors.

A quick look into dsm-firmenich

Explore dsm-firmenich, our businesses, and other highlights.

A new chapter in a long history

On May 9, 2023, two global leaders in science and innovation joined forces to create dsm-firmenich, a company that delivers new breakthroughs in nutrition, health, and beauty. 

Latest news

  • dsm-firmenich reports 2023 full year results

    15 Feb 2024

    Dimitri de Vreeze, CEO, commented: “We are proud that the company is already operating seamlessly with integration well ahead of plan, including the development of a common culture, as demonstrated in our recent employee engagement survey. Our employees have done a truly amazing job building momentum, positioning dsm-firmenich as a world leader in nutrition, health and beauty.

  • dsm-firmenich completes voluntary cash offer for DSM shares

    12 Feb 2024

    DSM-Firmenich AG (the Company or dsm-firmenich) and DSM B.V. (DSM) today announce that the Voluntary Tender Offer for the remaining DSM ordinary shares (previously Koninklijke DSM N.V. with ISIN: NL0000009827, the Shares) as announced on January 8, 2024 (the Voluntary Tender Offer) has been completed.

  • dsm-firmenich reports Q3 2023 results

    31 Oct 2023

    The company estimates for FY 2023, on a pro forma basis, an Adjusted EBITDA of around €1,800 million, which includes an estimated negative vitamin effect of about €500 million as well as a negative foreign exchange effect of about €90 million.

Any questions?

Whether you’re a shareholder, potential shareholder, or analyst, our Investor Relations team is on hand with the answers you’re looking for.

Explore more